Bionime Corporation (TPE:4737)

Bionime Statistics

Total Valuation

Bionime has a market cap or net worth of TWD 3.63 billion. The enterprise value is 6.24 billion.

Market Cap	3.63B
Enterprise Value	6.24B

Important Dates

The next estimated earnings date is Thursday, March 12, 2026.

Earnings Date	Mar 12, 2026
Ex-Dividend Date	n/a

Share Statistics

Bionime has 67.29 million shares outstanding. The number of shares has increased by 0.21% in one year.

Current Share Class	67.29M
Shares Outstanding	67.29M
Shares Change (YoY)	+0.21%
Shares Change (QoQ)	+0.03%
Owned by Insiders (%)	8.06%
Owned by Institutions (%)	0.63%
Float	38.51M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.90
PB Ratio	1.96
P/TBV Ratio	3.01
P/FCF Ratio	27.38
P/OCF Ratio	12.60
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 174.09, with an EV/FCF ratio of 47.00.

EV / Earnings	-51.83
EV / Sales	3.26
EV / EBITDA	174.09
EV / EBIT	n/a
EV / FCF	47.00

Financial Position

The company has a current ratio of 0.75, with a Debt / Equity ratio of 1.60.

Current Ratio	0.75
Quick Ratio	0.46
Debt / Equity	1.60
Debt / EBITDA	82.67
Debt / FCF	22.32
Interest Coverage	-2.05

Financial Efficiency

Return on equity (ROE) is -6.46% and return on invested capital (ROIC) is -1.70%.

Return on Equity (ROE)	-6.46%
Return on Assets (ROA)	-1.47%
Return on Invested Capital (ROIC)	-1.70%
Return on Capital Employed (ROCE)	-3.54%
Revenue Per Employee	3.83M
Profits Per Employee	-240,706
Employee Count	500
Asset Turnover	0.34
Inventory Turnover	2.52

Taxes

Income Tax	-59.72M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -5.45% in the last 52 weeks. The beta is 0.35, so Bionime's price volatility has been lower than the market average.

Beta (5Y)	0.35
52-Week Price Change	-5.45%
50-Day Moving Average	57.93
200-Day Moving Average	62.30
Relative Strength Index (RSI)	33.19
Average Volume (20 Days)	121,795

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Bionime had revenue of TWD 1.91 billion and -120.35 million in losses. Loss per share was -1.80.

Revenue	1.91B
Gross Profit	641.61M
Operating Income	-131.18M
Pretax Income	-179.55M
Net Income	-120.35M
EBITDA	25.96M
EBIT	-131.18M
Loss Per Share	-1.80

Balance Sheet

The company has 366.61 million in cash and 2.96 billion in debt, with a net cash position of -2.60 billion or -38.57 per share.

Cash & Cash Equivalents	366.61M
Total Debt	2.96B
Net Cash	-2.60B
Net Cash Per Share	-38.57
Equity (Book Value)	1.86B
Book Value Per Share	27.50
Working Capital	-471.19M

Cash Flow

In the last 12 months, operating cash flow was 288.36 million and capital expenditures -155.64 million, giving a free cash flow of 132.72 million.

Operating Cash Flow	288.36M
Capital Expenditures	-155.64M
Free Cash Flow	132.72M
FCF Per Share	1.97

Margins

Gross margin is 33.52%, with operating and profit margins of -6.85% and -6.29%.

Gross Margin	33.52%
Operating Margin	-6.85%
Pretax Margin	-9.38%
Profit Margin	-6.29%
EBITDA Margin	1.36%
EBIT Margin	-6.85%
FCF Margin	6.93%

Dividends & Yields

Bionime does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.21%
Shareholder Yield	-0.21%
Earnings Yield	-3.31%
FCF Yield	3.65%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on September 8, 2025. It was a forward split with a ratio of 1.0998680158.

Last Split Date	Sep 8, 2025
Split Type	Forward
Split Ratio	1.0998680158

Scores

Bionime has an Altman Z-Score of 0.81 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.81
Piotroski F-Score	2